Andrew J. Cowan

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Global Burden of Multiple Myeloma

Andrew J. Cowan, Christine A. Allen, Aleksandra Barać et al. · JAMA Oncology · 2018 · 634 citations · Full text

Medicine, Health Sciences, Oncology +16

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Margot J. Pont, Tyler Hill, Gabriel O. Cole et al. · Blood · 2019 · 324 citations · Full text

Life Sciences, Immunology, Oncology +14

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Jordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama et al. · Blood · 2020 · 212 citations · Full text

Life Sciences, Hematology, Immunology +13

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach et al. · The Lancet Haematology · 2023 · 153 citations

Medicine, Pharmacology, Pharmacotherapy +16